| Product Code: ETC7661125 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The import of rituximab to Israel in 2024 saw significant contributions from top exporting countries including Lithuania, Canada, Ireland, Germany, and China. Despite high concentration levels indicated by the Herfindahl-Hirschman Index (HHI), the market continued to grow steadily with a Compound Annual Growth Rate (CAGR) of 10.09% from 2020 to 2024. The growth momentum remained strong in 2024 with a growth rate of 7.1% compared to the previous year, reflecting a promising outlook for the rituximab market in Israel.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Rituximab Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Rituximab Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Rituximab Market - Industry Life Cycle |
3.4 Israel Rituximab Market - Porter's Five Forces |
3.5 Israel Rituximab Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.6 Israel Rituximab Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Israel Rituximab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in Israel |
4.2.2 Growing awareness and adoption of rituximab therapy in the Israeli healthcare system |
4.2.3 Favorable government policies and regulations supporting the use of rituximab in Israel |
4.3 Market Restraints |
4.3.1 High cost associated with rituximab treatment may limit access for some patients |
4.3.2 Potential side effects and safety concerns related to rituximab therapy |
4.3.3 Competition from alternative treatments or therapies in the Israeli market |
5 Israel Rituximab Market Trends |
6 Israel Rituximab Market, By Types |
6.1 Israel Rituximab Market, By Route of Administration |
6.1.1 Overview and Analysis |
6.1.2 Israel Rituximab Market Revenues & Volume, By Route of Administration, 2021- 2031F |
6.1.3 Israel Rituximab Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.1.4 Israel Rituximab Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.1.5 Israel Rituximab Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2 Israel Rituximab Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Israel Rituximab Market Revenues & Volume, By Non-Hodgkin's Lymphoma, 2021- 2031F |
6.2.3 Israel Rituximab Market Revenues & Volume, By Chronic Lymphocytic Leukemia, 2021- 2031F |
6.2.4 Israel Rituximab Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.5 Israel Rituximab Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Rituximab Market Import-Export Trade Statistics |
7.1 Israel Rituximab Market Export to Major Countries |
7.2 Israel Rituximab Market Imports from Major Countries |
8 Israel Rituximab Market Key Performance Indicators |
8.1 Number of healthcare facilities offering rituximab therapy in Israel |
8.2 Patient adherence and compliance rates to rituximab treatment |
8.3 Number of clinical trials or research studies on rituximab conducted in Israel |
9 Israel Rituximab Market - Opportunity Assessment |
9.1 Israel Rituximab Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.2 Israel Rituximab Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Israel Rituximab Market - Competitive Landscape |
10.1 Israel Rituximab Market Revenue Share, By Companies, 2024 |
10.2 Israel Rituximab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |